PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30864294-7 2019 Nevirapine users with hepatotoxicity overrepresented genotypes CYP2B6 TT and 516GT+TT as compared to efavirenz users (47.83% vs. 45.45%, OR = 6.88, 65.22% vs. 54.55%, OR = 1.56). Nevirapine 0-10 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 63-69 33060725-0 2020 Effects of CYP2B6 polymorphisms on plasma nevirapine concentrations: a systematic review and meta-analysis. Nevirapine 42-52 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 11-17 33060725-1 2020 Cytochrome P450 (CYP) is involved in the metabolism of nevirapine (NVP); especially, CYP2B6 has been known to be one of the main enzymes involved in NVP metabolism. Nevirapine 55-65 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 85-91 33060725-7 2020 We found that carriers of the CYP2B6 516TT genotype had a 2.18 microg/mL higher NVP concentration than did the GG or GT (95% CI 1.28-3.08). Nevirapine 80-83 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 30-36 30864294-8 2019 Similarly, in nevirapine +alcohol users with hepatotoxicity, the frequency of CYP2B6 516GT, 516GT+TT genotypes was higher than with nevirapine +alcohol nonusers (40.0% vs. 11.11%, OR = 8.00, 80.0% vs. 27.78%, OR = 4.00). Nevirapine 14-24 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 78-84 30864294-10 2019 Likewise, in HIV patients, genotypes CYP2B6 516GT, 516GT+TT were predominant with nevirapine +alcohol users as compared to nevirapine +alcohol nonusers (57.89% vs. 34.57%, OR = 2.46; 78.95% vs. 69.14%, OR = 1.67). Nevirapine 82-92 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 37-43 30864294-10 2019 Likewise, in HIV patients, genotypes CYP2B6 516GT, 516GT+TT were predominant with nevirapine +alcohol users as compared to nevirapine +alcohol nonusers (57.89% vs. 34.57%, OR = 2.46; 78.95% vs. 69.14%, OR = 1.67). Nevirapine 123-133 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 37-43 27707991-0 2017 Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. Nevirapine 80-90 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 29-35 28187506-7 2017 Nevirapine group: CYP2B6 516G>T was associated with higher log10 Cmax and lower log10 Cmin . Nevirapine 0-10 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 18-24 26891286-5 2016 Efavirenz (EFV) and nevirapine (NVP) are the major components of HAART both metabolized by CYP2B6, an enzyme that can potentially be inhibited or induced by compounds found in medicinal plant extracts. Nevirapine 20-30 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 91-97 26626330-10 2016 Both compounds induced several drug metabolizing genes (including CYP2B6, CYP3A4 and UGT1A1), mediated by CAR activation in Nevirapine and PXR in Ritonavir. Nevirapine 124-134 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 66-72 27709010-5 2016 CYP2B6 has been demonstrated to play a role in the metabolism of 2%-10% of clinically used drugs including widely used antineoplastic agents cyclophosphamide and ifosfamide, anesthetics propofol and ketamine, synthetic opioids pethidine and methadone, and the antiretrovirals nevirapine and efavirenz, among others. Nevirapine 276-286 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 27195527-0 2016 Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. Nevirapine 18-28 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 63-69 27195527-3 2016 RESULTS: CYP2B6 516 G>T and 983 T>C were associated independently with plasma nevirapine concentrations in pregnant (n=110) and postpartum (n=122) women and were used for stratification. Nevirapine 84-94 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 9-15 26247717-0 2015 CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon. Nevirapine 58-68 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 26415139-6 2015 Thus, CYP2B6 is a crucial enzyme in the metabolism of antiretroviral drugs, efavirenz and nevirapine. Nevirapine 90-100 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 6-12 26348712-0 2015 Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients. Nevirapine 50-60 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 11-17 26348712-4 2015 This study, therefore, aimed to identify sources of variability in nevirapine pharmacokinetics and pharmacodynamics, focusing on genetic variation in CYP2B6 and CYP1A2. Nevirapine 67-77 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 150-156 26348712-7 2015 CYP2B6 and CYP1A2 were chosen as the candidate genes based on reports in literature, as well as their prominence in the metabolism of efavirenz, a drug in the same class with nevirapine. Nevirapine 175-185 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 26348712-13 2015 We conclude that CYP2B6 c.516G>T and CYP2B6 c.983T>C could be important sources of nevirapine pharmacokinetic variability that could be considered for dosage optimization, while CYP1A2 g.-163C>A seems to be associated with HIV disease progression. Nevirapine 89-99 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 17-23 26348712-13 2015 We conclude that CYP2B6 c.516G>T and CYP2B6 c.983T>C could be important sources of nevirapine pharmacokinetic variability that could be considered for dosage optimization, while CYP1A2 g.-163C>A seems to be associated with HIV disease progression. Nevirapine 89-99 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 40-46 25878720-1 2015 BACKGROUND: Polymorphisms in cytochrome P450 2B6 (CYP2B6) affect the steady state plasma concentration of nevirapine. Nevirapine 106-116 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 29-48 25878720-1 2015 BACKGROUND: Polymorphisms in cytochrome P450 2B6 (CYP2B6) affect the steady state plasma concentration of nevirapine. Nevirapine 106-116 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 50-56 25878720-10 2015 RESULTS: Women with CYP2B6 516TT genotype (n=9) had higher mean nevirapine plasma levels (14.33 mug/mL) compared to those with heterozygous 516GT (9.18 mug/mL; n=25) and wild- type 516GG (7.95 mug/mL; n=32) genotypes (P=0.01). Nevirapine 64-74 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 20-26 25878720-11 2015 Women heterozygous for the CYP2B6 983TC genotype (n=13) had higher mean nevirapine plasma levels (12.94 mug/mL), compared to women with the homozygous 983TT (8.35 mug/mL; n=53) genotype (P=0.007). Nevirapine 72-82 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 27-33 25878720-15 2015 CONCLUSIONS: CYP2B6 516G>T and CYP2B6 983T>C genotypes were strongly associated with plasma nevirapine concentration, which predicted immunologic response in women on nevirapine-based antiretroviral therapy. Nevirapine 98-108 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 13-19 25878720-15 2015 CONCLUSIONS: CYP2B6 516G>T and CYP2B6 983T>C genotypes were strongly associated with plasma nevirapine concentration, which predicted immunologic response in women on nevirapine-based antiretroviral therapy. Nevirapine 98-108 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 34-40 23774940-0 2013 Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. Nevirapine 45-55 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 20-26 23982262-10 2013 A trend toward higher nevirapine AUC(0-6 h) for the CYP2B6 516TT (rs3745274; Q172H) genotype was observed in European Americans (P=0.19). Nevirapine 22-32 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 52-58 24517233-3 2013 The CYP2B6 516TT genotype and male gender were significantly associated with occurrence of Efavirenz induced central nervous system disorders (OR 20.58, p=0.004) and the ABCB1 rs10276036TT genotype with Nevirapine induced skin hypersensitivity (OR 4.01, p=0.04). Nevirapine 203-213 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 4-10 22462748-1 2012 AIM: Hepatic enzymes, CYP2B6 and UGT2B7 play a major role in the metabolism of the widely used antiretroviral drugs efavirenz, nevirapine and zidovudine. Nevirapine 127-137 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 22-28 23687222-1 2013 OBJECTIVE: Nevirapine is metabolized by cytochrome P450 (CYP) 2B6 and CYP3A4. Nevirapine 11-21 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 40-65 23687222-10 2013 CONCLUSIONS: The effects on plasma drug exposure following single-dose nevirapine may be greater for CYP2B6 983T C than for 516G T and are less pronounced than at steady state. Nevirapine 71-81 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 101-107 23439719-6 2012 Associations were identified with HLA-Cw*04, HLA-B*35, HLA-DRB*01 and CYP2B6 516G>T (rs3745274); however, positive predictive values for these genetic markers were low, and most nevirapine-associated adverse events occurred in patients without these markers. Nevirapine 181-191 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 70-76 23104099-9 2012 In bivariate linear regression, CYP2B6 516G T (CYP2B6*6) was associated with lower nevirapine clearances (P=3.5x10). Nevirapine 83-93 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 32-38 23104099-9 2012 In bivariate linear regression, CYP2B6 516G T (CYP2B6*6) was associated with lower nevirapine clearances (P=3.5x10). Nevirapine 83-93 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 47-53 22680342-0 2012 Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. Nevirapine 38-48 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 13-19 22680342-1 2012 WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Nevirapine pharmacokinetics are affected by several factors including CYP2B6 single nucleotide polymorphisms (SNPs). Nevirapine 44-54 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 114-120 22680342-7 2012 CYP2B6 (both at position 516 and 983) but not ABCB1 (3435 and 1236) SNPs as well as age correlate with higher nevirapine exposure. Nevirapine 110-120 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 21860339-11 2011 CONCLUSION: By integration of high-throughput genotyping data into a pharmacometric analysis of nevirapine, the impact of the CYP2B6 516G>T polymorphism on nevirapine"s exposure was confirmed and quantified. Nevirapine 96-106 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 126-132 22082652-14 2012 Multivariate regression analysis identified carriage of a composite genotype of ABCC10 rs2125739 and CYP2B6 516G>T (P=0.001), time post dose (P=0.01) and BMI (P=0.07) to be independently associated with nevirapine plasma concentrations. Nevirapine 206-216 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 101-107 22111602-5 2012 CYP2B6 516G>T (non-wild-type/wild-type) correlated with nevirapine pharmacokinetic parameters; geometric mean ratios (95% CI): 1.75 (1.27-2.40) for area under the concentration time curve (AUC)(0-12 h), 1.58 (1.03-2.42) for C(0), and 0.53 (0.31-0.91) for clearance. Nevirapine 59-69 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 22111602-8 2012 The T allele for CYP2B6 516 was significantly associated with nevirapine exposure. Nevirapine 62-72 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 17-23 21441248-1 2011 BACKGROUND: Nevirapine is metabolized by CYP2B6 and polymorphisms within the CYP2B6 gene partly explain inter-patient variability in pharmacokinetics. Nevirapine 12-22 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 41-47 21393201-3 2011 OBJECTIVES: To study the influence of age, drug dose and formulation type, nutritional status and CYP2B6 516G>T polymorphism on blood concentrations of nevirapine in children treated with generic antiretroviral drugs. Nevirapine 155-165 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 98-104 21441248-1 2011 BACKGROUND: Nevirapine is metabolized by CYP2B6 and polymorphisms within the CYP2B6 gene partly explain inter-patient variability in pharmacokinetics. Nevirapine 12-22 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 77-83 21441248-2 2011 The aim of this study was to model the complex relationship between nevirapine exposure, weight and genetics (based on combined analysis of CYP2B6 516G > T and 983T > C single nucleotide polymorphisms). Nevirapine 68-78 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 140-146 20338069-1 2010 BACKGROUND: Cytochrome P450 2B6 (CYP2B6) metabolizes efavirenz and nevirapine, the major core antiretroviral drugs for HIV in Thailand. Nevirapine 67-77 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 12-31 20338069-1 2010 BACKGROUND: Cytochrome P450 2B6 (CYP2B6) metabolizes efavirenz and nevirapine, the major core antiretroviral drugs for HIV in Thailand. Nevirapine 67-77 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 33-39 20338069-6 2010 The frequencies of GG, GT and TT genotypes of CYP2B6-G516T were 38.46%, 47.69% and 13.85% in efavirenz group and 44.07%, 52.54% and 3.39% in nevirapine group, respectively. Nevirapine 141-151 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 46-52 20338069-12 2010 CONCLUSIONS: CYP2B6-TT genotype had impact on plasma efavirenz and nevirapine concentrations, while rifampicin co-administration had only small effects. Nevirapine 67-77 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 13-19 19702527-4 2009 CYP2B6 can metabolise approximately 8% of clinically used drugs (n > 60), including cyclophosphamide, ifosfamide, tamoxifen, ketamine, artemisinin, nevirapine, efavirenz, bupropion, sibutramine, and propofol. Nevirapine 151-161 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 19812066-8 2009 CONCLUSIONS: The CYP2B6 516G>T impact on nevirapine concentrations was less pronounced after intra-partum single-dose nevirapine than reported under steady-state conditions, perhaps due to lack of enzyme auto-induction at the time of dosing. Nevirapine 44-54 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 17-23 19812066-8 2009 CONCLUSIONS: The CYP2B6 516G>T impact on nevirapine concentrations was less pronounced after intra-partum single-dose nevirapine than reported under steady-state conditions, perhaps due to lack of enzyme auto-induction at the time of dosing. Nevirapine 121-131 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 17-23 18781911-5 2008 These individual differences may result in variable systemic exposure to drugs metabolized by CYP2B6, including the antineoplastics cyclophosphamide and ifosfamide, the antiretrovirals nevirapine and efavirenz, the anesthetics propofol and ketamine, the synthetic opioid methadone, and the anti-Parkinsonian selegiline. Nevirapine 185-195 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 94-100 19228205-0 2009 Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. Nevirapine 76-86 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-19 19228205-1 2009 OBJECTIVES: The aim of the study was to characterize the impact of the cytochrome P450 2B6 (CYP2B6), CYP3A4, CYP3A5 and ATP-binding cassette sub-family B member 1 (ABCB1) polymorphisms on nevirapine plasma concentrations. Nevirapine 188-198 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 71-90 19228205-1 2009 OBJECTIVES: The aim of the study was to characterize the impact of the cytochrome P450 2B6 (CYP2B6), CYP3A4, CYP3A5 and ATP-binding cassette sub-family B member 1 (ABCB1) polymorphisms on nevirapine plasma concentrations. Nevirapine 188-198 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 92-98 19228205-9 2009 The association between CYP2B6 516G-->T and higher plasma nevirapine exposure was maintained at both bid and qd dosing. Nevirapine 61-71 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 24-30 19239339-1 2009 BACKGROUND: Polymorphisms in CYP2B6 affect the steady-state plasma concentrations of nevirapine and efavirenz. Nevirapine 85-95 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 29-35 19239339-11 2009 Exploratory analyses suggested possible associations between additional CYP2B6 polymorphisms and the pharmacokinetics of nevirapine and efavirenz. Nevirapine 121-131 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 72-78 18281305-9 2008 CONCLUSIONS: This is the first report that the 983T>C genotype (part of the CYP2B6*18 haplotype) impacts on nevirapine plasma concentrations and the first study to assess the impact of 983C homozygosity on efavirenz concentrations. Nevirapine 111-121 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 79-85 17352764-11 2007 CONCLUSIONS: CYP2B6 G516T significantly influenced nevirapine trough concentrations in HIV-infected patients in Uganda. Nevirapine 51-61 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 13-19 21197270-5 2008 Other studies have shown associations of the CYP2B6-G516T genotype with nevirapine pharmacokinetics and central nervous system adverse effects related to efavirenz use. Nevirapine 72-82 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 45-51 18090046-1 2007 BACKGROUND: Cytochrome P450 2B6 (CYP2B6)-G516T genotype is associated with altered activity of hepatic CYP2B6 and efavirenz pharmacokinetics, but the relationship between the CYP2B6-G516T genotype and nevirapine (NVP) pharmacokinetics in plasma and cerebrospinal fluid (CSF) is limited. Nevirapine 201-211 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 12-31 18090046-1 2007 BACKGROUND: Cytochrome P450 2B6 (CYP2B6)-G516T genotype is associated with altered activity of hepatic CYP2B6 and efavirenz pharmacokinetics, but the relationship between the CYP2B6-G516T genotype and nevirapine (NVP) pharmacokinetics in plasma and cerebrospinal fluid (CSF) is limited. Nevirapine 201-211 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 33-39 18090046-1 2007 BACKGROUND: Cytochrome P450 2B6 (CYP2B6)-G516T genotype is associated with altered activity of hepatic CYP2B6 and efavirenz pharmacokinetics, but the relationship between the CYP2B6-G516T genotype and nevirapine (NVP) pharmacokinetics in plasma and cerebrospinal fluid (CSF) is limited. Nevirapine 201-211 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 103-109 18090046-1 2007 BACKGROUND: Cytochrome P450 2B6 (CYP2B6)-G516T genotype is associated with altered activity of hepatic CYP2B6 and efavirenz pharmacokinetics, but the relationship between the CYP2B6-G516T genotype and nevirapine (NVP) pharmacokinetics in plasma and cerebrospinal fluid (CSF) is limited. Nevirapine 201-211 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 103-109 15864119-1 2005 BACKGROUND: Efavirenz (EFV) and nevirapine (NVP) are metabolized by cytochrome P450 2B6 (CYP2B6). Nevirapine 32-42 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 68-87 15864119-1 2005 BACKGROUND: Efavirenz (EFV) and nevirapine (NVP) are metabolized by cytochrome P450 2B6 (CYP2B6). Nevirapine 32-42 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 89-95 32815870-8 2021 CYP2B6 poor metabolizers had greater efavirenz concentrations at all weeks and greater nevirapine concentrations at baseline. Nevirapine 87-97 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 17003847-3 2006 Since nevirapine-induced hepatotoxicity commonly occurs between 2-12 weeks of treatment, and nevirapine is a known inducer of human CYP3A and CYP2B6 isozymes, it was envisaged that the hepatotoxicity was due to activation of nevirapine to toxic metabolites by the induced enzymes. Nevirapine 93-103 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 142-148 17003847-3 2006 Since nevirapine-induced hepatotoxicity commonly occurs between 2-12 weeks of treatment, and nevirapine is a known inducer of human CYP3A and CYP2B6 isozymes, it was envisaged that the hepatotoxicity was due to activation of nevirapine to toxic metabolites by the induced enzymes. Nevirapine 93-103 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 142-148 14628297-13 2004 Our data could explain why the plasma concentration ratio of R/S methadone is variable and why drugs that induce CYP2B6 such as nevirapine and efavirenz also induce methadone metabolism, while the CYP3A4 inducer rifabutin has no effect on methadone pharmacokinetics. Nevirapine 128-138 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 113-119 35484635-5 2022 Composite CYP2B6*6/*18 genotype was significantly associated with trough plasma nevirapine levels (geometric mean (standard deviation): 4482 ng/ml (1349) of normal metabolizers vs. 4632 ng/ml (1793) of intermediate metabolizers vs. 6229 ng/ml (2549) of poor metabolizers; P < 0.001), but not the plasma HIV RNA levels, absolute lymphocyte and CD4+ T lymphocyte counts. Nevirapine 80-90 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 10-16 35484635-7 2022 Composite CYP2B6*6/*18 genotype correlated with plasma nevirapine levels but not immunologic and virologic responses. Nevirapine 55-65 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 10-16 35512066-0 2022 The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Nevirapine 52-62 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 12-18 33833550-0 2021 Erratum: Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana [Corrigendum]. Nevirapine 68-78 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 24-30 33758532-0 2021 Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana. Nevirapine 59-69 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 15-21 33758532-1 2021 Purpose: CYP2B6 liver enzyme metabolizes the two non-nucleoside reverse transcriptase inhibitors Efavirenz (EFV) and Nevirapine (NVP) used in the antiretroviral therapy (ART) regimens for HIV-infected individuals. Nevirapine 117-127 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 9-15 33758532-1 2021 Purpose: CYP2B6 liver enzyme metabolizes the two non-nucleoside reverse transcriptase inhibitors Efavirenz (EFV) and Nevirapine (NVP) used in the antiretroviral therapy (ART) regimens for HIV-infected individuals. Nevirapine 129-132 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 9-15